ClinicalTrials.gg
TerminatedNCT02978716Updated Mar 23, 2022Results posted

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

A Phase 2 interventional study of Trilaciclib and Gemcitabine in Triple-Negative Breast Neoplasms, Breast Neoplasm and Breast Cancer, sponsored by G1 Therapeutics, Inc.. Terminated at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 2, Interventional, and Treatment

Why this study was terminated
Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing gemcitabine in Triple Negative Breast Neoplasms — 2 open to participants now, 5 under way, 2 of them phase 3. Gemcitabine · Triple Negative Breast Neoplasms.

Enrollment
7th of 13
102 · median 102
Started
2017
with 1 other
Phase 2
8 of 13
2 open now
Registered
6th of 13
by date
Lead sponsor
1 of 13
G1 Therapeutics, Inc.

Among the 13 studies testing gemcitabine in Triple Negative Breast Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 6th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

2 of the 13 studies testing gemcitabine in Triple Negative Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing gemcitabine in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for participants with metastatic triple negative breast cancer.

The study was an open-label and 102 participants were randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups:

  • Group 1: GC therapy (Days 1 and 8 of 21-day cycles) only (n=34)
  • Group 2: GC therapy (Days 1 and 8) plus trilaciclib (G1T28) on Days 1 and 8 of 21-day cycles (n=33)
  • Group 3: GC therapy (Days 2 and 9) plus trilaciclib (G1T28) on Days 1, 2, 8, and 9 of 21-day cycles (n=35)

The study included 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit.

Read the detailed description

The posted results represent the final results of Study G1T28-04, a Phase 2 study of the safety, efficacy and pharmacokinetics of trilaciclib (G1T28) in patients with locally recurrent/metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapy.

The final myelopreservation efficacy results are reported from database lock 1 ([DBL1], data cut-off [DCO] date of 30 July 2018). Final anti-tumor efficacy (ORR, PFS), and final summary exposure and safety data are reported from database lock 2 ([DBL2], DCO 28 June 2019) which occurred to support filing of the trilaciclib New Drug Application (NDA). Final overall survival (OS) data are reported from the final database lock which occurred on 17 July 2020 (with a last patient last visit date of 28 February 2020).

03

Conditions studied

  • Triple-Negative Breast Neoplasms
  • Breast Neoplasm
  • Breast Cancer
  • Triple-Negative Breast Cancer

Keywords

  • Breast Cancer
  • CDK 4/6 Inhibitor
  • Triple Negative Breast Cancer
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of hormone receptor (HR)-negative, human epidermal growth factor receptor 2 ()-negative (locally recurrent or TNBC) breast cancer
  • Available TNBC diagnostic tumor tissue (archived tissue allowed)
  • Evaluable disease
  • (ECOG) performance status 0 to 1
  • Adequate organ function
  • Predicted of 3 or more months

Exclusion criteria

Exclusion Criteria:

  • More than 2 prior chemotherapy regimens for locally recurrent or TNBC. If > 12 months have elapsed between the date of last /neoadjuvant chemotherapy administration and first documented local or distant disease recurrence the therapy will not be considered a in the locally recurrent or metastatic TNBC setting.
  • or requiring immediate treatment with radiation therapy or .
  • drug within 30 days of first trilaciclib (G1T28) dose
  • Concurrent radiotherapy, radiotherapy within 14 days of first trilaciclib (G1T28) dose
  • Cytotoxic chemotherapy within 3 weeks of first trilaciclib (G1T28) dose
  • Prior hematopoietic stem cell or bone marrow transplantation
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Group 1: Gemcitabine/Carboplatin (Days 1 and 8)

    Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square \[mg/m\^2\] and carboplatin area under the curve \[AUC\] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).

    Drug: Gemcitabine · Drug: Carboplatin

  • Experimental
    Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8)

    Participants received IV infusion of trilaciclib 240 mg/m\^2 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.

    Drug: Trilaciclib · Drug: Gemcitabine · Drug: Carboplatin

  • Experimental
    Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)

    Participants received IV infusion of trilaciclib 240 mg/m\^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.

    Drug: Trilaciclib · Drug: Gemcitabine · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1

    DSN was defined as the number of days from the date of the first absolute neutrophil count (ANC) value of less than (\<) 0.5 × 10\^9 cells/liter (L) observed between Day 1 Cycle 1 and the end of Cycle 1 to the date of the first ANC value greater than or equal to (\>=) 0.5 × 10\^9/L that met the following: (1) occurred after the ANC value of \< 0.5 × 10\^9 cells/L and (2) no other ANC values \< 0.5 × 10\^9 cells/L occurred between this day and the end of Cycle 1. Severe neutropenia (SN) was set to zero for participants who did not experience severe (Grade 4) neutropenia in Cycle 1, including those who were randomized but never treated.

    Time frame: From randomization to the end of Cycle 1 (Each cycle= 21 days)

  2. Number of Participants With Severe (Grade 4) Neutropenia (SN)

    Number of participants with Grade 4 SN was a binary variable. If a participants had at least 1 ANC value \< 0.5 ×10\^9/L during the treatment period, the participants was assigned as "yes" to the occurrence of SN. Otherwise, it was "no".

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

Secondary outcomes

  1. Number of Participants With Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    BOR was defined as the best response across all time points (RECIST v1.1). The best overall response was determined once all the data for the participant is known. Each participant has been assigned one of the following categories (RECIST 1.1): complete response (CR): disappearance of all target lesions; partial response (PR): \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progression disease (PD): \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study); stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD); NE: not evaluable and missing.

    Time frame: From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days

  2. Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator

    DOR is the time between first response by RECIST Version 1.1 of CR or PR and the first date that progressive disease is documented by RECIST Version 1.1, or death. Participants who do not experience PD or death was censored at the last tumor assessment date. 95% Confidence Interval (CI) was calculated using the Kaplan-Meier method.

    Time frame: From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days

  3. Overall Survival (OS)

    Overall survival was defined as the time (months) from date of randomization to the date of death due to any cause. Participants who do not die during the study were censored at the date last known to be alive. The OS was calculated using Kaplan-Meier method.

    Time frame: From date of randomization to date of death due to any cause, assessed up to a maximum of 1120 days

  4. Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator

    PFS was defined as the time (months) from date of randomization until date of documented PD or death due to any cause, whichever comes first. PD: \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study). The PFS was calculated using Kaplan-Meier method.

    Time frame: From date of randomization until the occurrence of disease progression, death due to any cause or a censoring event, assessed up to a maximum of 875 days

  5. Relative Dose Intensity of Gemcitabine and Carboplatin

    Relative dose intensity was defined as 100% times the actual dose intensity divided by the planned dose intensity. The planned dose intensity was defined as the cumulative planned dose through the study divided by (number of cycles × 3 weeks). Relative dose intensity (%) was calculated as: for gemcitabine (100 \* \[Dose intensity (mg/m2/week) / (2000/3 (mg/m2/week)\]); for carboplatin (100 \* \[Dose intensity (AUC/week)/ (4/3) (AUC/week)\]) and for trilaciclib (100 \* \[Dose intensity (mg/m2/week)/ (480 /3 (mg/m2/week)\] for Group 2 and 100 \* \[Dose intensity (mg/m2/week) / (960 /3 (mg/m2/week)\] for Group 3).

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  6. Duration of Exposure

    Duration of exposure (days) = First dose date of study drug from the last cycle - first dose date of study drug + 21.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  7. Number of Cycles Participants Received Treatment in Each Treatment Arm

    Participants were considered to have started a cycle if they have received at least 1 dose of any study drug.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  8. Cumulative Dose of Gemcitabine

    Cumulative dose: Sum of the total doses by cycle administered to a participant in the duration of exposure, i.e. total number of cycles received (milligram per meter square \[mg/m\^2\]).

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  9. Cumulative Dose of Carboplatin

    Cumulative dose: Sum of the total doses by cycle (AUC) administered to a participant in the duration of exposure, i.e. total number of cycles received (in total prescribed AUC).

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  10. Maximum Observed Plasma Concentration (Cmax) of Trilaciclib

    The observed peak plasma concentration was determined from the plasma concentration-versus time data.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  11. Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib

    AUC0-t was calculated with the linear/log-trapezoidal method, which uses linear interpolation between data points to calculate the AUC. The linear/log-trapezoidal method will be employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method will be used for those arising from decreasing concentrations.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  12. Terminal Elimination Half-Life (t1/2) of Trilaciclib

    t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve, the actual body exposure to drug after administration of a dose of the drug ( in mg\*h/L).

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  13. Maximum Observed Plasma Concentration (Cmax) of Gemcitabine

    The observed peak plasma concentration was determined from the plasma concentration-versus time data.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  14. Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Gemcitabine

    AUC0-t was calculated with the linear/log-trapezoidal method.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  15. Terminal Elimination Half-Life (t1/2) of Free Carboplatin

    t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  16. Clearance (CL) of of Free Carboplatin

    Clearance after intravenous infusion administration was calculated as: CL=Dose/AUC0-inf. AUC0-inf was calculated as: AUC0-inf=AUClast+Clast/lambdaz where Clast is the last quantifiable concentration in the terminal elimination phase.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  17. Volume of Distribution at Steady State (Vss) of Free Carboplatin

    Vss was the volume of distribution at steady state of free carboplatin was reported.

    Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)

  18. Number of Participants With Grade 3 and 4 Hematologic Toxicities

    Hematologic toxicities events were defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 hematologic toxicities was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 hematologic toxicities during the treatment period, the participant was assigned as Yes to the occurrence of Grade 3 and 4 hematologic toxicities; otherwise, it was No. If a participant did not have an event, the value of 0 was assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  19. Number of Participants With Grade 3 or 4 Thrombocytopenia

    Hematologic toxicities events are defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 thrombocytopenia was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 thrombocytopenia during the treatment period, the participant was assigned as "Yes" to the occurrence of Grade 3 and 4 thrombocytopenia; otherwise, it was "No". If a participant did not have an event, the value of 0 was assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  20. Major Adverse Hematologic Event (MAHE) Rate

    MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelosuppression into a single endpoint by summing of the total number of events across a set of pre-specified components.The individual components for MAHE were all-cause hospitalizations, all-cause dose reductions, febrile neutropenia, prolonged severe neutropenia (duration \> 5 days), RBC transfusion and platelet transfusion. Event rate for MAHE was calculated as the number of events/durations of treatment period divided by 7 days/1 week.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  21. Number of Participants With Febrile Neutropenia (FN)

    The criterion for identifying FN was if the PT was "FEBRILE NEUTROPENIA" the occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  22. Number of Participants With Infection SAEs

    Number of participants with infection SAEs during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion for identifying the proper infection SAE records was as follows: If the system organ class (SOC) from Medical Dictionary for Regulatory Activities (MedDRA) takes value "INFECTIONS AND INFESTATIONS," and the AE was a serious event.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  23. Number of Participants With Red Blood Cell (RBC) Transfusions On/After Week 5 (Day 35)

    Each RBC transfusion with a unique start date on/after 5 weeks on study during the treatment period was defined as a separate event. Occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

    Time frame: From Day 35 through the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 508 days

  24. Number of Participants With Platelet Transfusions

    Each platelet transfusion with a unique start date during the treatment period was defined as a separate event. The occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if the total number of events \>=1 was observed and No for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  25. Number of Participants With Granulocyte Colony-stimulating Factor (G-CSF) Administration

    The criterion for selecting proper records is as follows: If the chemical subgroup from the World Health Organization-Drug Dictionary (WHO-DD) takes value "COLONY STIMULATING FACTOR," the medication was classified as G-CSF. The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  26. Number of Participants With Erythropoiesis Stimulating Agent (ESA) Administration

    The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion to select proper records was as follows: If the chemical subgroup from WHO-DD Version September 2017 (i.e., TEXT4 for CODE4) takes value "OTHER ANTIANEMIC PREPARATIONS", the medication was classified as ESAs.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  27. Number of Participants With Intravenous Antibiotics Use

    The criteria for identifying an IV antibiotic administration event was (1) if the Therapeutic subgroup from WHO-DD version takes value "ANTIBACTERIALS FOR SYSTEMIC USE", and (2) the route of medication was "intravenous" or the route was "other" with the detailed specification as "IVPB". The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  28. All-cause Dose Reductions, Event Rate (Per Cycle)

    Dose reductions were not permitted for trilaciclib. Dose reductions for gemcitabine or carboplatin were collected on the dosing page. No more than 3 dose modifications for toxicity in total were allowed for any participant. All dose reductions were counted as a separate event. Discontinuations of an individual component of the chemotherapy regimen were counted as a dose reduction If the participant continued the other chemotherapy drug as a monotherapy. Event rate was calculated as the total number of cycles with an event divided by the total number of cycles.

    Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days

  29. Dose Modifications: Number of Participants With Cycle Delays

    Dose modifications was summarized for each study drug based on number of cycles received during the treatment period. If the participant was unable to start a new cycle at that next visit, then the cycle is delayed, the reason entered, and the question was asked again at the next visit until the participant either starts a new cycle or discontinues treatment.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  30. Dose Modifications - Number of Participants With Skipped Doses

    Dose modifications was summarized for each study drug based on skipped doses not received during the treatment period. Primary reasons for skipped doses included toxicity, investigator decision and administrative reasons (e.g., holidays).

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  31. Dose Modifications: Number of Participants With Any Dose Interruptions

    Dose interruptions was defined as interruption of infusion, regardless of whether the study drug was continued after the interruption.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

  32. Dose Modifications - Number of Participants With Dose Reductions

    Dose (mg/m2) reductions were not permitted for trilaciclib. Dose reductions for carboplatin and gemcitabine were determined by comparing the planned dose on the respective drug administration pages between the current cycle and the previous cycle.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An Adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. Any AE that started on or after the first dose of study drugs was included as a TEAE. A Serious AE was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) and regardless of causality that met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. TEAEs included serious and non-serious TEAEs.

    Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 1116 days

07

Results

Posted Mar 23, 2022
Limitations and caveats
Limitations of this study are the small sample size and open-label design. Antitumor outcomes were not the primary endpoints.

Participant flow

This study was conducted at 34 sites in the United States (US), Belgium, Bulgaria, Croatia, Republic of Macedonia, and Serbia from 02 February 2017 (first participant enrolled) to 28 February 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Started343335
Itt population343335
Safety analysis set303335
Treated303335
Completed000
Not completed343335
Withdrew: Death251320
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject645
Withdrew: Sponsor terminated2139
Withdrew: Other130

Outcome measures

PrimaryDuration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1

DSN was defined as the number of days from the date of the first absolute neutrophil count (ANC) value of less than (\<) 0.5 × 10\^9 cells/liter (L) observed between Day 1 Cycle 1 and the end of Cycle 1 to the date of the first ANC value greater than or equal to (\>=) 0.5 × 10\^9/L that met the following: (1) occurred after the ANC value of \< 0.5 × 10\^9 cells/L and (2) no other ANC values \< 0.5 × 10\^9 cells/L occurred between this day and the end of Cycle 1. Severe neutropenia (SN) was set to zero for participants who did not experience severe (Grade 4) neutropenia in Cycle 1, including those who were randomized but never treated.

Time frame:
From randomization to the end of Cycle 1 (Each cycle= 21 days)
Reported as:
Mean · days
Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1
daysGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 11 ± 2.22 ± 3.51 ± 2.6
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · Analysis of covariance (ANCOVA) · p = 0.7048 (A Hochberg-based gatekeeping procedure was used to control the global family-wise error rate across the multiple null hypotheses in the strong sense at a 1-sided 0.025 level.) · Mean difference: 0.3 · 95% CI -0.8 to 1.5
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · ANCOVA · p = 0.3364 (2-sided p-value was calculated using a ANCOVA with study baseline ANC value as covariate, stratification factors of lines of systemic therapy, liver involvement and treatment as fixed effects.) · Mean difference: 0.8 · 95% CI -0.6 to 2.3
PrimaryNumber of Participants With Severe (Grade 4) Neutropenia (SN)

Number of participants with Grade 4 SN was a binary variable. If a participants had at least 1 ANC value \< 0.5 ×10\^9/L during the treatment period, the participants was assigned as "yes" to the occurrence of SN. Otherwise, it was "no".

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Severe (Grade 4) Neutropenia (SN)
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Grade 4 neutropenia: Yes9128
Grade 4 neutropenia: No252127
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · Modified Poisson method · p = 0.7048 (A 1-sided p-value was calculated using Hochberg-based gatekeeping procedure to control the global familywise error rate across the multiple null hypotheses.) · Adjusted rate ratio: 0.776 · 95% CI 0.386 to 1.559
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · Modified Poisson Regression · p = 0.9154 (The p-value was calculated using modified Poisson method adjusting for number of cycles, accounting for the number of prior lines of therapy (0 versus 1 - 2) and liver involvement as the stratification factors and baseline ANC as a covariate.) · Adjusted rate ratio: 0.961 · 95% CI 0.457 to 2.019
SecondaryNumber of Participants With Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

BOR was defined as the best response across all time points (RECIST v1.1). The best overall response was determined once all the data for the participant is known. Each participant has been assigned one of the following categories (RECIST 1.1): complete response (CR): disappearance of all target lesions; partial response (PR): \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progression disease (PD): \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study); stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD); NE: not evaluable and missing.

Time frame:
From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Complete response (CR)000
Partial response (PR)71511
Stable disease (SD)11915
Progressive disease (PD)653
Not evaluable (NE)001
Missing011
SecondaryDuration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator

DOR is the time between first response by RECIST Version 1.1 of CR or PR and the first date that progressive disease is documented by RECIST Version 1.1, or death. Participants who do not experience PD or death was censored at the last tumor assessment date. 95% Confidence Interval (CI) was calculated using the Kaplan-Meier method.

Time frame:
From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days
Reported as:
Median · months
Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator
monthsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator7.8 (7.5 to NA)11.5 (4.8 to 17.8)9.6 (3.1 to 12.6)
SecondaryOverall Survival (OS)

Overall survival was defined as the time (months) from date of randomization to the date of death due to any cause. Participants who do not die during the study were censored at the date last known to be alive. The OS was calculated using Kaplan-Meier method.

Time frame:
From date of randomization to date of death due to any cause, assessed up to a maximum of 1120 days
Reported as:
Median · months
Overall Survival (OS)
monthsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Overall Survival (OS)12.6 (6.3 to 15.6)NA (10.2 to NA)17.8 (12.9 to 32.7)
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · stratified log-rank test · p = 0.0004 (P-value was calculated using the stratified log-rank test to account for the number of prior lines of therapy (0 versus 1 - 2) and liver involvement as the stratification factors.) · Adjusted hazard ratio (hr): 0.40 · 95% CI 0.22 to 0.74Cox regression model.
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · stratified log-rank test · p = 0.0016 (P-value was calculated using the stratified log-rank test to account for the number of prior lines of therapy (0 versus 1 - 2) and liver involvement as the stratification factors.) · Adjusted hr: 0.31 · 95% CI 0.15 to 0.63Cox regression model.
SecondaryProgression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator

PFS was defined as the time (months) from date of randomization until date of documented PD or death due to any cause, whichever comes first. PD: \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study). The PFS was calculated using Kaplan-Meier method.

Time frame:
From date of randomization until the occurrence of disease progression, death due to any cause or a censoring event, assessed up to a maximum of 875 days
Reported as:
Median · months
Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator
monthsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator5.7 (3.3 to 9.2)9.4 (6.1 to 11.9)7.3 (6.2 to 13.9)
SecondaryRelative Dose Intensity of Gemcitabine and Carboplatin

Relative dose intensity was defined as 100% times the actual dose intensity divided by the planned dose intensity. The planned dose intensity was defined as the cumulative planned dose through the study divided by (number of cycles × 3 weeks). Relative dose intensity (%) was calculated as: for gemcitabine (100 \* \[Dose intensity (mg/m2/week) / (2000/3 (mg/m2/week)\]); for carboplatin (100 \* \[Dose intensity (AUC/week)/ (4/3) (AUC/week)\]) and for trilaciclib (100 \* \[Dose intensity (mg/m2/week)/ (480 /3 (mg/m2/week)\] for Group 2 and 100 \* \[Dose intensity (mg/m2/week) / (960 /3 (mg/m2/week)\] for Group 3).

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Mean · percentage of dose
Relative Dose Intensity of Gemcitabine and Carboplatin
percentage of doseGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Carboplatin77.5 ± 19.2079.1 ± 15.8881.7 ± 16.09
Gemcitabine79.1 ± 18.2980.8 ± 12.5181.0 ± 14.49
SecondaryDuration of Exposure

Duration of exposure (days) = First dose date of study drug from the last cycle - first dose date of study drug + 21.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Median · days
Duration of Exposure
daysGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Duration of Exposure101 (21 to 469)161 (42 to 637)168 (21 to 436)
SecondaryNumber of Cycles Participants Received Treatment in Each Treatment Arm

Participants were considered to have started a cycle if they have received at least 1 dose of any study drug.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Mean · number of cycles
Number of Cycles Participants Received Treatment in Each Treatment Arm
number of cyclesGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Number of Cycles Participants Received Treatment in Each Treatment Arm6 ± 5.09 ± 6.68 ± 4.8
SecondaryCumulative Dose of Gemcitabine

Cumulative dose: Sum of the total doses by cycle administered to a participant in the duration of exposure, i.e. total number of cycles received (milligram per meter square \[mg/m\^2\]).

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Mean · mg/m^2
Cumulative Dose of Gemcitabine
mg/m^2Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Cumulative Dose of Gemcitabine10694.3 ± 9029.1114680.9 ± 11557.9013277.2 ± 8722.51
SecondaryCumulative Dose of Carboplatin

Cumulative dose: Sum of the total doses by cycle (AUC) administered to a participant in the duration of exposure, i.e. total number of cycles received (in total prescribed AUC).

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Mean · AUC (mg/mL/min)
Cumulative Dose of Carboplatin
AUC (mg/mL/min)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Cumulative Dose of Carboplatin20.3 ± 16.4727.8 ± 21.2126.0 ± 16.33
SecondaryMaximum Observed Plasma Concentration (Cmax) of Trilaciclib

The observed peak plasma concentration was determined from the plasma concentration-versus time data.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Trilaciclib
ng/mLGroup 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Maximum Observed Plasma Concentration (Cmax) of Trilaciclib—2280 ± 17901630 ± 423
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib

AUC0-t was calculated with the linear/log-trapezoidal method, which uses linear interpolation between data points to calculate the AUC. The linear/log-trapezoidal method will be employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method will be used for those arising from decreasing concentrations.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · hour* nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib
hour* nanogram per milliliter (h*ng/mL)Group 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib—3610 ± 18703800 ± 910
SecondaryTerminal Elimination Half-Life (t1/2) of Trilaciclib

t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve, the actual body exposure to drug after administration of a dose of the drug ( in mg\*h/L).

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Median · hours
Terminal Elimination Half-Life (t1/2) of Trilaciclib
hoursGroup 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Terminal Elimination Half-Life (t1/2) of Trilaciclib—5.27 (3.98 to 6.64)5.31 (4.36 to 6.29)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Gemcitabine

The observed peak plasma concentration was determined from the plasma concentration-versus time data.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine
microgram per milliliter (mcg/mL)Group 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Maximum Observed Plasma Concentration (Cmax) of GemcitabineNA ± NA18.0 ± 4.0423.8 ± 25.9
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Gemcitabine

AUC0-t was calculated with the linear/log-trapezoidal method.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · hour*microgram per milliliter (h*mcg/mL)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Gemcitabine
hour*microgram per milliliter (h*mcg/mL)Group 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of GemcitabineNA20.4 ± 11.615.4 ± 7.11
SecondaryTerminal Elimination Half-Life (t1/2) of Free Carboplatin

t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Median · hours
Terminal Elimination Half-Life (t1/2) of Free Carboplatin
hoursGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Terminal Elimination Half-Life (t1/2) of Free Carboplatin5.232.49 (1.32 to 2.93)1.79 (1.35 to 4.86)
SecondaryClearance (CL) of of Free Carboplatin

Clearance after intravenous infusion administration was calculated as: CL=Dose/AUC0-inf. AUC0-inf was calculated as: AUC0-inf=AUClast+Clast/lambdaz where Clast is the last quantifiable concentration in the terminal elimination phase.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · Liter/hour (L/h)
Clearance (CL) of of Free Carboplatin
Liter/hour (L/h)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Clearance (CL) of of Free Carboplatin6.6514.0 ± 2.8013.7 ± 4.48
SecondaryVolume of Distribution at Steady State (Vss) of Free Carboplatin

Vss was the volume of distribution at steady state of free carboplatin was reported.

Time frame:
Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Reported as:
Mean · Liter
Volume of Distribution at Steady State (Vss) of Free Carboplatin
LiterGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Volume of Distribution at Steady State (Vss) of Free Carboplatin44.435.0 ± 12.034.0 ± 8.99
SecondaryNumber of Participants With Grade 3 and 4 Hematologic Toxicities

Hematologic toxicities events were defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 hematologic toxicities was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 hematologic toxicities during the treatment period, the participant was assigned as Yes to the occurrence of Grade 3 and 4 hematologic toxicities; otherwise, it was No. If a participant did not have an event, the value of 0 was assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 and 4 Hematologic Toxicities
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with Grade 3 and 4 hematologic toxicities: Yes253027
Participants with Grade 3 and 4 hematologic toxicities: No938
SecondaryNumber of Participants With Grade 3 or 4 Thrombocytopenia

Hematologic toxicities events are defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 thrombocytopenia was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 thrombocytopenia during the treatment period, the participant was assigned as "Yes" to the occurrence of Grade 3 and 4 thrombocytopenia; otherwise, it was "No". If a participant did not have an event, the value of 0 was assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Thrombocytopenia
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Number of Participants With Grade 3 or 4 Thrombocytopenia211219
SecondaryMajor Adverse Hematologic Event (MAHE) Rate

MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelosuppression into a single endpoint by summing of the total number of events across a set of pre-specified components.The individual components for MAHE were all-cause hospitalizations, all-cause dose reductions, febrile neutropenia, prolonged severe neutropenia (duration \> 5 days), RBC transfusion and platelet transfusion. Event rate for MAHE was calculated as the number of events/durations of treatment period divided by 7 days/1 week.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Number · event rate per week
Major Adverse Hematologic Event (MAHE) Rate
event rate per weekGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Major Adverse Hematologic Event (MAHE) Rate0.1530.1080.080
SecondaryNumber of Participants With Febrile Neutropenia (FN)

The criterion for identifying FN was if the PT was "FEBRILE NEUTROPENIA" the occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia (FN)
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Number of Participants With Febrile Neutropenia (FN)110
SecondaryNumber of Participants With Infection SAEs

Number of participants with infection SAEs during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion for identifying the proper infection SAE records was as follows: If the system organ class (SOC) from Medical Dictionary for Regulatory Activities (MedDRA) takes value "INFECTIONS AND INFESTATIONS," and the AE was a serious event.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Infection SAEs
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with Infection SAEs: Yes200
Participants with Infection SAEs: No323335
SecondaryNumber of Participants With Red Blood Cell (RBC) Transfusions On/After Week 5 (Day 35)

Each RBC transfusion with a unique start date on/after 5 weeks on study during the treatment period was defined as a separate event. Occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

Time frame:
From Day 35 through the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 508 days
Reported as:
Count of participants · Participants
Number of Participants With Red Blood Cell (RBC) Transfusions On/After Week 5 (Day 35)
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with RBC transfusions on/after Week 5: Yes12118
Participants with RBC transfusions on/after Week 5: No222227
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · modified Poisson regression · p = 0.7048 (A 1-sided p-value was calculated using Hochberg-based gatekeeping procedure to control the global familywise error rate across the multiple null hypotheses.) · Adjusted hr: 0.493 · 95% CI 0.226 to 1.073
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · Modified Poisson Regression · p = 0.7272 (P-value was calculated using modified Poisson method adjusting for duration of treatment in days accounting for number of prior lines of therapy (0 versus 1 - 2); liver involvement as the stratification factors and baseline hemoglobin as a covariate.) · Adjusted rate ratio: 0.885 · 95% CI 0.447 to 1.754
SecondaryNumber of Participants With Platelet Transfusions

Each platelet transfusion with a unique start date during the treatment period was defined as a separate event. The occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if the total number of events \>=1 was observed and No for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Platelet Transfusions
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with platelet transfusion: Yes436
Participants with platelet transfusion: No303029
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · modified Poisson regression · p = 0.7048 (A 1-sided p-value was calculated using Hochberg-based gatekeeping procedure to control the global familywise error rate across the multiple null hypotheses.) · Adjusted rate ratio: 0.988 · 95% CI 0.294 to 3.317
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · Modified Poisson Regression · p = 0.4078 (P-value: calculated using modified Poisson method adjusting for duration of treatment in days accounting for number of prior lines of therapy (0 versus 1 - 2); liver involvement as stratification factors and baseline platelet count as a covariate.) · Adjusted rate ratio: 0.527 · 95% CI 0.116 to 2.399
SecondaryNumber of Participants With Granulocyte Colony-stimulating Factor (G-CSF) Administration

The criterion for selecting proper records is as follows: If the chemical subgroup from the World Health Organization-Drug Dictionary (WHO-DD) takes value "COLONY STIMULATING FACTOR," the medication was classified as G-CSF. The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Granulocyte Colony-stimulating Factor (G-CSF) Administration
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with G-CSF Administration: Yes162114
Participants with G-CSF Administration: No181221
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · modified Poisson regression · p = 0.7048 (A 1-sided p-value was calculated using Hochberg-based gatekeeping procedure to control the global familywise error rate across the multiple null hypotheses.) · Adjusted rate ratio: 0.645 · 95% CI 0.362 to 1.150
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · Modified Poisson Regression · p = 0.7835 (P-value was calculated using modified Poisson method adjusting for number of cycles, accounting for the number of prior lines of therapy (0 versus 1 - 2) and liver involvement as the stratification factors and baseline ANC as a covariate.) · Adjusted rate ratio: 0.936 · 95% CI 0.583 to 1.502
SecondaryNumber of Participants With Erythropoiesis Stimulating Agent (ESA) Administration

The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion to select proper records was as follows: If the chemical subgroup from WHO-DD Version September 2017 (i.e., TEXT4 for CODE4) takes value "OTHER ANTIANEMIC PREPARATIONS", the medication was classified as ESAs.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Erythropoiesis Stimulating Agent (ESA) Administration
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with ESA Administration: Yes423
Participants with ESA Administration: No303132
SecondaryNumber of Participants With Intravenous Antibiotics Use

The criteria for identifying an IV antibiotic administration event was (1) if the Therapeutic subgroup from WHO-DD version takes value "ANTIBACTERIALS FOR SYSTEMIC USE", and (2) the route of medication was "intravenous" or the route was "other" with the detailed specification as "IVPB". The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Count of participants · Participants
Number of Participants With Intravenous Antibiotics Use
ParticipantsGroup 1: Gemcitabine/Carboplatin (Day 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with Intravenous Antibiotics Use: Yes650
Participants with Intravenous Antibiotics Use: No282835
SecondaryAll-cause Dose Reductions, Event Rate (Per Cycle)

Dose reductions were not permitted for trilaciclib. Dose reductions for gemcitabine or carboplatin were collected on the dosing page. No more than 3 dose modifications for toxicity in total were allowed for any participant. All dose reductions were counted as a separate event. Discontinuations of an individual component of the chemotherapy regimen were counted as a dose reduction If the participant continued the other chemotherapy drug as a monotherapy. Event rate was calculated as the total number of cycles with an event divided by the total number of cycles.

Time frame:
During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Reported as:
Number · event rate per cycle
All-cause Dose Reductions, Event Rate (Per Cycle)
event rate per cycleGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
All-cause Dose Reductions, Event Rate (Per Cycle)0.1410.1180.133
Statistical analysis
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) · negative binomial regression · p = 0.7048 (The 1-sided p-value was calculated using Hochberg-based gatekeeping procedure to control the global family wise error rate across the multiple null hypotheses.) · Adjusted rate ratio: 0.991 · 95% CI 0.475 to 2.067
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) · negative binomial regression · p = 0.5541 (P-value was calculated using negative binomial method adjusting for number of cycles, accounting for the number of prior lines of therapy (0 versus 1 - 2) and liver involvement as the stratification factors.) · Adjusted rate ratio: 0.820 · 95% CI 0.426 to 1.580
SecondaryDose Modifications: Number of Participants With Cycle Delays

Dose modifications was summarized for each study drug based on number of cycles received during the treatment period. If the participant was unable to start a new cycle at that next visit, then the cycle is delayed, the reason entered, and the question was asked again at the next visit until the participant either starts a new cycle or discontinues treatment.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Count of participants · Participants
Dose Modifications: Number of Participants With Cycle Delays
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Dose Modifications: Number of Participants With Cycle Delays171922
SecondaryDose Modifications - Number of Participants With Skipped Doses

Dose modifications was summarized for each study drug based on skipped doses not received during the treatment period. Primary reasons for skipped doses included toxicity, investigator decision and administrative reasons (e.g., holidays).

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Count of participants · Participants
Dose Modifications - Number of Participants With Skipped Doses
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Dose Modifications - Number of Participants With Skipped Doses152013
SecondaryDose Modifications: Number of Participants With Any Dose Interruptions

Dose interruptions was defined as interruption of infusion, regardless of whether the study drug was continued after the interruption.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Count of participants · Participants
Dose Modifications: Number of Participants With Any Dose Interruptions
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
TrilaciclibNA35
Carboplatin110
Gemcitabine240
SecondaryDose Modifications - Number of Participants With Dose Reductions

Dose (mg/m2) reductions were not permitted for trilaciclib. Dose reductions for carboplatin and gemcitabine were determined by comparing the planned dose on the respective drug administration pages between the current cycle and the previous cycle.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Reported as:
Count of participants · Participants
Dose Modifications - Number of Participants With Dose Reductions
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Carboplatin101315
Gemcitabine132017
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. Any AE that started on or after the first dose of study drugs was included as a TEAE. A Serious AE was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) and regardless of causality that met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. TEAEs included serious and non-serious TEAEs.

Time frame:
During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 1116 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
Participants with any TEAEs303334
Participants with any Serious TEAEs10114

Adverse events

Collected over From date of randomization up to 1121 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Gemcitabine/Carboplatin (Days 1 and 8)25/30 (83.3%)10/30 (33.3%)30/30 (100%)
Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8)13/33 (39.4%)11/33 (33.3%)33/33 (100%)
Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)20/35 (57.1%)4/35 (11.4%)34/35 (97.1%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
CellulitisInfections and infestations2/300/330/35
Platelet count decreasedInvestigations0/302/330/35
Pleural effusionRespiratory, thoracic and mediastinal disorders0/302/330/35
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/302/330/35
HypertensionVascular disorders1/300/330/35
HypotensionVascular disorders1/300/330/35
PainGeneral disorders1/300/330/35
Acute myocardial infarctionCardiac disorders1/300/330/35
Right ventricular failureCardiac disorders1/300/330/35
DyspnoeaRespiratory, thoracic and mediastinal disorders1/301/330/35
Most frequent other events
Showing 10 of 87
Most frequent other events
EventGroup 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)
AnaemiaBlood and lymphatic system disorders22/3016/3315/35
NauseaGastrointestinal disorders7/3014/3317/35
FatigueGeneral disorders11/3014/3316/35
NeutropeniaBlood and lymphatic system disorders13/3015/3312/35
ThrombocytopeniaBlood and lymphatic system disorders13/3013/3311/35
HeadacheNervous system disorders6/309/3314/35
Neutrophil count decreasedInvestigations8/3012/3311/35
Platelet count decreasedInvestigations8/308/3312/35
VomitingGastrointestinal disorders8/308/3311/35
DyspnoeaRespiratory, thoracic and mediastinal disorders3/309/336/35

Baseline characteristics

The ITT analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)Total
Mean55 ± 13.656 ± 12.158 ± 9.556 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)Total
Female343235101
Male0101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)Total
Hispanic or Latino2529
Not Hispanic or Latino32283393
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Gemcitabine/Carboplatin (Days 1 and 8)Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8)Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)Total
American Indian or Alaska Native0000
Asian0246
Native Hawaiian or Other Pacific Islander0000
Black or African American57214
White28222878
More than one race0000
Unknown or Not Reported1214
08

Study locations

54 sites
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Disney Family Cancer Center
    Burbank, California 91505, United States
  • Sharp Clinical Oncology
    San Diego, California 92123, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Memorial UC Health
    Colorado Springs, Colorado 80909, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Florida Cancer Research Institute, LLC.
    Plantation, Florida 33324, United States
  • Florida Cancer Specialists - North (FCS North)
    Saint Petersburg, Florida 33705, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Florida Cancer Specialists - East (FCS East)
    West Palm Beach, Florida 33401, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Community Health Network
    Indianapolis, Indiana 46250, United States
  • University of Maryland Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201-1544, United States
  • The University of Maryland St. Joseph Medical Center
    Towson, Maryland 21204, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64113, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Levine Cancer Center
    Charlotte, North Carolina 28204, United States
  • Forsyth Memorial Hospital, Novant Health Oncology Specialists
    Winston-Salem, North Carolina 27103, United States
  • Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Austin, Texas 75231, United States
  • Texas Oncology, P.A.
    Austin, Texas 78745, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology-El Paso Cancer Treatment Center Grandview
    El Paso, Texas 79902, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Texas Oncology-San Antonio Northeast
    San Antonio, Texas 78217, United States
  • Tyler Hematology-Oncology, PA
    Tyler, Texas 75701, United States
  • Texas Oncology, P.A.
    Tyler, Texas 75702, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Antwerp University Hospital (UZA)
    Edegem, 10 2650, Belgium
  • University Multiprofile Hospital for Active Treatment
    Sofia, 1000, Bulgaria
  • MHAT for Womens Health - Nadezhda OOD
    Sofia, 1330, Bulgaria
  • Special Hospital For Active Treatment In Oncology
    Sofia, 1756, Bulgaria
  • Multiprofile Hospital for Active Treatment
    Varna, 9000, Bulgaria
  • University Hospital Centre Osijek
    Osijek, 31000, Croatia
  • General Hospital Varaždin
    Varazdin, 42000, Croatia
  • University Hospital Centre "Sestre milosrdnice"
    Zagreb, 10000, Croatia
  • University Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Clinical Hospital Dr. Trifun Panovski
    Bitola, 7000, North Macedonia
  • University Clinic of Radiotherapy and Oncology
    Skopje, 1000, North Macedonia
  • Special Hospital for Internal Diseases , Oncomed
    Belgrade, 11000, Serbia
  • Clinical Hospital Centre Bezanijska Kosa, Oncology Clinic
    Belgrade, 11070, Serbia
  • Center for Oncology and Radiotherapy, Clinical Centre
    Kragujevac, 34000, Serbia
  • Clinical Centre Nis, Clinic of Oncology
    Nis, 18000, Serbia
  • Oncology Institute of Vojvodina, Clinic for Internal Oncology
    Sremska Kamenica, 21204, Serbia
  • Mammacentrum, Sv.Agáty
    Banská Bystrica, 974 01, Slovakia
  • Cancer Institute VOU, Rastislavova
    Košice, 040 01, Slovakia
  • University Medical Centre Maribor
    Maribor, 2000, Slovenia
09

References and documents

Publications

  • Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnovic Z, Vasev N, Ma L, Richards DA, Wilks ST, Milenkovic D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019 Nov;20(11):1587-1601. doi: 10.1016/S1470-2045(19)30616-3. Epub 2019 Sep 28. PubMed 31575503 ↗
  • Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnovic Z, Vasev N, Ma L, Richards DA, Wilks ST, Milenkovic D, Xiao J, Sorrentino J, Horton J, O'Shaughnessy J. Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clin Cancer Res. 2022 Feb 15;28(4):629-636. doi: 10.1158/1078-0432.CCR-21-2272. PubMed 34887261 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jun 2019, 28 months.

Results were first posted in Mar 2022, 2 years 8 months after primary completion. A results delay was requested in Jul 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2016
First posted
Dec 1, 2016
StartActual
Feb 2, 2017
Primary completionActual
Jun 28, 2019
CompletionActual
Feb 28, 2020
Results delay requested
Jul 18, 2019
Results first posted
Mar 23, 2022
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02978716
Responsible party
Sponsor
First posted
Dec 1, 2016
Start date
Feb 2, 2017
Primary completion
Jun 28, 2019
Completion
Feb 28, 2020
Results posted
Mar 23, 2022
Last update
Mar 23, 2022

Study contacts

Clinical Contact
study director · G1 Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Carboplatin

Start the discussion